依达拉奉对急性脑梗死患者血清BNP、CRP、Hcy水平的影响

Abstract
Figure/Table
References (18)
Related Citation (15)

Download: PDF (503 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the application effect of Edaravone in patients with acute cerebral infarction (ACI).Methods A total of 64 ACI patients admitted to the Second People′s Hospital of Yichun City from September 2019 to March 2021 were selected as the study subjects,and they were divided into study group and control group according to random number table method,with 32 patients in each group.The control group received Aspirin routine treatment,the study group plus Edaravone treatment.The clinical efficacy,serological indexes,degree of neurological deficit and adverse reactions were compared between the two groups.Results The total effective rate of the study group was higher than that of the control group,the difference was statistically significant (P＜0.05).Before treatment,there were no significant differences in the levels of brain natriuretic peptide (BNP),C-reactive protein (CRP) and homocysteine (Hcy)between two groups (P＞0.05).After treatment,the levels of BNP,CRP and Hcy in the study group were lower than those in the control group,and the differences were statistically significant (P＜0.05).Before treatment,there was no significant difference in the scores of National Institutes of Health stroke scale (NIHSS) between the two groups (P＞0.05).After treatment,NIHSS score of the study group was lower than that of the control group,and the difference was statistically significant (P＜0.05).There was no significant difference in the total incidence of adverse reactions between the two groups (P＞0.05).Conclusion Edaravone can effectively improve the levels of serum BNP,CRP and Hcy in patients with acute cerebral infarction,reduce inflammatory reaction and facilitate the recovery of neurological function.

Key words： Acute cerebral infarction Edaravone Serological indexes Degree of neurological deficit

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZENG Qing
	LI Xiaolian

Cite this article:

ZENG Qing,LI Xiaolian. Effect of Edaravone on serum BNP,CRP and Hcy levels in patients with acute cerebral infarction[J]. 中国当代医药, 2022, 29(7): 64-66转70.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2022/V29/I7/64

[3]	祝善尧，葛伟，张欢，等.血栓通联合阿司匹林对急性脑梗死患者凝血纤溶功能及血清神经递质的影响[J].临床神经病学杂志，2020，33（1）：27-31.
[4]	张淑芬.尤瑞克林联合依达拉奉治疗急性脑梗死的临床疗效分析[J].实用临床医药杂志，2017，21（21）：149-150.
[5]	张圣琼，余丹，杨国帅，等.依达拉奉联合尼莫地平对急性脑梗死患者神经功能与炎性因子水平的影响观察[J].中国急救医学，2020，40（6）：494-500.
[6]	中华医学会神经病学分会，中华医学会神经病学分会脑血管病学组.中国急性缺血性脑卒中诊治指南2014[J].中华神经科杂志，2015，48（4）：246-257.
[7]	陶子荣.我国脑卒中患者临床神经功能缺损评分标准信度，效度及敏感度的评价[J].第二军医大学学报，2009，30（3）：283-285.
[8]	张薇，刘威，王英，等.亚低温联合依达拉奉治疗急性脑梗死的疗效及对血清hs-CRP，NSE，S100-β 蛋白水平的影响[J].中西医结合心脑血管病杂志，2019，17（19）：3029-3033.
[9]	詹骐魁，叶胜业，林森，等.依达拉奉治疗急性脑梗死的临床疗效及对氧化应激和炎症因子的影响[J].贵州医药，2018，42（7）：816-818.
[10]	王挺刚，桂树华，狄美琪，等.阿司匹林、氯吡格雷联合疏血通注射液治疗急性脑梗死的临床效果及对血液流变学的影响[J].临床误诊误治，2019，32（1）：54-57.
[11]	张继业，安萍.阿司匹林联合硫酸氢氯吡格雷口服治疗急性脑梗死的有效性和安全性分析[J].中国实用医药，2019，14（16）：92-93.
[12]	张钟少，陆磊，邝素雅，等.经颅磁刺激对急性脑梗死患者血清Hcy 及CRP 的影响[J].中国医药科学，2020，10（3）：251-253.
[13]	朱新岭，陈颖，杨君君，等.丁苯酞联合依达拉奉对老年急性脑梗死患者抗氧化能力、炎性反应及神经功能恢复的影响[J].广西医学，2018，40（16）：1828-1832.
[14]	李慧.东菱迪芙联合依达拉奉对老年脑梗死患者血清血管内皮生长因子，同型半胱氨酸和肿瘤坏死因子α 的影响[J].实用临床医药杂志，2017，21（1）：22-22.
[15]	辛茹，秦付绕.尤瑞克林联合依达拉奉对急性脑梗死患者血清同型半胱氨酸、血清超敏C-反应蛋白及D-二聚体水平的影响[J].药物评价研究，2019，42（1）：122-125.
[1]	范红娟.长春西汀联合依达拉奉治疗急性脑梗死疗效及对血浆炎性因子的影响[J].现代中西医结合杂志，2017，26（19）：2126-2128.
[2]	庞伟，李洪涛，程弘宇，等.阿加曲班联合依达拉奉治疗急性脑梗死的效果观察[J].解放军医药杂志，2017，29（4）：70-74.
[16]	孙凡，刘恒，徐倩倩，等.依达拉奉注射液对急性脑梗死溶栓患者MMP-9 水平、出血性转化以及神经功能缺损评分的影响[J].心脑血管病防治，2019，19（3）：252-254.
[17]	杨育生，刘振鹏，黄耀忠.依达拉奉联合长春西汀注射液治疗急性脑梗死的临床效果[J].中国当代医药，2020，27（9）：57-60.
[18]	杨帆，白抚生，尤林，等.依达拉奉对脑缺血再灌注损伤患者神经功能、氧化应激和炎性反应的影响[J].疑难病杂志，2020，19（9）：880-883，887.